Vertex Pharmaceuticals (1VRTX) Stock Forecast & Price Target
1VRTX Analyst Ratings
Strong Buy
21Buy3Hold0Sell
Based on 24 analysts giving stock ratings to Vertex Pharmaceuticals in the past 3 months
1VRTX Stock 12 Month Forecast
Average Price Target
EUR 543.04â–²(8.33% Upside)Based on 24 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is EUR 543.04 with a high forecast of EUR 648.23 and a low forecast of EUR 395.20. The average price target represents a 8.33% change from the last price of EUR 501.30.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 648.23
AverageEUR 543.04
LowEUR 395.20
Highest Price TargetHighestEUR 648.23Average Price TargetEUR 543.04Lowest Price TargetLowestEUR 395.20
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Michael Yee | UBS | EUR 549.88→EUR 572.23 | buy | 14.15%Upside | Reiterated | 11/03/26 | ||
| Geoff Meacham | Citi | EUR 523.05 | buy | 4.34%Upside | Reiterated | 11/03/26 | ||
| Jessica Fye | J.P. Morgan | EUR 500.70→EUR 509.64 | buy | 1.66%Upside | Assigned | 11/03/26 | ||
| Salveen Richter | Goldman Sachs | EUR 584.75→EUR 648.23 | buy | 29.31%Upside | Assigned | 11/03/26 | ||
| Terence Flynn | Morgan Stanley | EUR 594.58→EUR 590.11 | buy | 17.72%Upside | Assigned | 11/03/26 | ||
| Paul Matteis | Stifel Nicolaus | EUR 447.05→EUR 503.38 | hold | 0.42%Upside | Reiterated | 11/03/26 | ||
| Louise Chen | Scotiabank | EUR 498.91→EUR 590.11 | buy | 17.72%Upside | Reiterated | 11/03/26 | ||
| Mohit Bansal | Wells Fargo | EUR 491.76→EUR 581.17 | buy | 15.93%Upside | Assigned | 11/02/26 | ||
| Carter Gould | Cantor Fitzgerald | EUR 532.00→EUR 553.45 | buy | 10.40%Upside | Reiterated | 11/02/26 | ||
| Brian Abrahams | RBC Capital | EUR 515.01→EUR 536.47 | buy | 7.01%Upside | Reiterated | 11/02/26 | ||
| Tazeen Ahmad | Bank of America Securities | EUR 596.37 | buy | 18.96%Upside | Reiterated | 11/02/26 | ||
| David Risinger | Leerink Partners | ― | buy | ― | Reiterated | 10/27/26 | ||
| Andrew Fein | H.C. Wainwright | EUR 573.12 | buy | 14.33%Upside | Reiterated | 10/26/26 | ||
| Phil Nadeau | TD Cowen | EUR 491.76 | buy | -1.90%Downside | Assigned | 10/26/26 | ||
| Evan Seigerman | BMO Capital | EUR 536.47 | buy | 7.01%Upside | Reiterated | 10/12/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Michael Yee | 11/03/26 | EUR 549.88→EUR 572.23 | buy | 14.15%Upside | Reiterated | UBS | ||
| Geoff Meacham | 11/03/26 | EUR 523.05 | buy | 4.34%Upside | Reiterated | Citi | ||
| Jessica Fye | 11/03/26 | EUR 500.70→EUR 509.64 | buy | 1.66%Upside | Assigned | J.P. Morgan | ||
| Salveen Richter | 11/03/26 | EUR 584.75→EUR 648.23 | buy | 29.31%Upside | Assigned | Goldman Sachs | ||
| Terence Flynn | 11/03/26 | EUR 594.58→EUR 590.11 | buy | 17.72%Upside | Assigned | Morgan Stanley | ||
| Paul Matteis | 11/03/26 | EUR 447.05→EUR 503.38 | hold | 0.42%Upside | Reiterated | Stifel Nicolaus | ||
| Louise Chen | 11/03/26 | EUR 498.91→EUR 590.11 | buy | 17.72%Upside | Reiterated | Scotiabank | ||
| Mohit Bansal | 11/02/26 | EUR 491.76→EUR 581.17 | buy | 15.93%Upside | Assigned | Wells Fargo | ||
| Carter Gould | 11/02/26 | EUR 532.00→EUR 553.45 | buy | 10.40%Upside | Reiterated | Cantor Fitzgerald | ||
| Brian Abrahams | 11/02/26 | EUR 515.01→EUR 536.47 | buy | 7.01%Upside | Reiterated | RBC Capital | ||
| Tazeen Ahmad | 11/02/26 | EUR 596.37 | buy | 18.96%Upside | Reiterated | Bank of America Securities | ||
| David Risinger | 10/27/26 | ― | buy | ― | Reiterated | Leerink Partners | ||
| Andrew Fein | 10/26/26 | EUR 573.12 | buy | 14.33%Upside | Reiterated | H.C. Wainwright | ||
| Phil Nadeau | 10/26/26 | EUR 491.76 | buy | -1.90%Downside | Assigned | TD Cowen | ||
| Evan Seigerman | 10/12/26 | EUR 536.47 | buy | 7.01%Upside | Reiterated | BMO Capital |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Vertex Pharmaceuticals
3 Months
Success Rate26/35 ratings generated profit
74%
Average Return
+7.99%
Copying Mohit Bansal's trades and holding each position for 3 Months would result in 74.29% of your transactions generating a profit, with an average return of +7.99% per trade.
1 Year
Success Rate20/25 ratings generated profit
80%
Average Return
+13.99%
Copying Salveen Richter's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +13.99% per trade.
2 Years
Success Rate19/19 ratings generated profit
100%
Average Return
+21.28%
Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +21.28% per trade.
1VRTX Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 50 | 59 | 70 | 62 | 47 |
| Hold | 9 | 9 | 9 | 6 | 3 |
| Sell | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 60 | 69 | 80 | 68 | 50 |
In the current month, 1VRTX has received 47 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 1VRTX average Analyst price target in the past 3 months is 543.04.
1VRTX Financial Forecast
HighEUR 4.83
ConsensusEUR 3.92
LowEUR 3.39
1VRTX Earnings Forecast
Next quarter’s earnings estimate for 1VRTX is EUR 3.92 with a range of EUR 3.39 to EUR 4.83. The previous quarter’s EPS was EUR 4.26. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 3.23B
ConsensusEUR 3.14B
LowEUR 3.08B
1VRTX Sales Forecast
Next quarter’s sales forecast for 1VRTX is EUR 3.14B with a range of EUR 3.08B to EUR 3.23B. The previous quarter’s sales results were EUR 3.08B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
1VRTX Stock Forecast FAQ
What is IT:1VRTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is €543.04.
What is IT:1VRTX’s upside potential, based on the analysts’ average price target?
Vertex Pharmaceuticals has 8.33% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Vertex Pharmaceuticals a Buy, Sell or Hold?
Vertex Pharmaceuticals has a consensus rating of Strong Buy, which is based on 21 buy ratings, 3 hold ratings and 0 sell ratings.
What is Vertex Pharmaceuticals’s share price target?
The average share price target for Vertex Pharmaceuticals is €543.04. This is based on 24 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €648.23, and the lowest forecast is €395.20. The average share price target represents a 8.33% increase from the current price of €501.3.
What do analysts say about Vertex Pharmaceuticals?
Vertex Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 24 Wall Street analysts.
How can I buy shares of Vertex Pharmaceuticals?
To buy shares of IT:1VRTX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
